SOD1 and amyotrophic lateral sclerosis: On March 22, 2023 Tofersen received a 9–0 vote from the FDA’s advisory committee on Peripheral and central nervous system drugs, and is expected to receive accelerated approval to treat SOD1-ALS patients.